Country wise analysis of startups with funds raising

Asia-Pacific is home to 9,905 active life sciences startups, as of July 20, 2025, according to Tracxn. Of these, 4,289 have secured funding, and 1,840 have advanced to Series A or later stages.

- 

While the concentration of startups varies across countries, the region continues to show steady momentum in new company formation with an average of 453 life sciences startups launched annually over the past decade.

China

Total startups: 3,060

Funding in 2025 (till June): $471 million

China’s rise on the global stage has been impressive. In 2024, one-third of all biotech assets licensed by Big Pharma originated from China, a sharp increase from less than 10 per cent in 2017. These innovations span oncology, immunology, diabetes, and increasingly, platform technologies such as antibody-drug conjugates (ADCs), cell therapies, and AI-assisted drug discovery. Of the 3,060 life sciences companies in China, 1,676 have secured funding. Among these, 848 have reached Series A or higher, and 532 have progressed to Series B or beyond. Over the past decade, China’s life sciences sector has attracted more than $38.7 billion in total funding. As of 2025, the sector has raised $471 million to date. (Source:Tracxn)

India

Total startups: 2,561